CRO inVentiv Health Clinical has appointed Dawn Anderson president of phase II-IV development, Martin Birkhofer chief medical officer and Richard Shimota chief financial officer.

Anderson has clinical and drug development and operational expertise. Most recently was global head of clinical operations and transformation at Cognizant, where she built the business from start to a global organization. Her experience includes leadership roles across clinical development and operations, portfolio and program management and process optimization at pharmaceutical and biotech companies, startups and CROs.

Previously, Anderson held senior roles at Quintiles, including vice president of global clinical operations and vice president of internal medicine.

In the newly created role of chief medical officer, Birkhofer, a medical oncologist, will oversee strategic investment in areas that expand upon inVentiv Health Clinical's capabilities. He will advise the business on industry trends and issues and build relationships with chief medical officers and senior executives within client organizations.

A 19-year veteran of Bristol-Myers Squibb, Birkhofer most recently was vice president, business development, leading global search, evaluation and diligence for worldwide business development. Previously, Birkhofer managed global medical affairs for oncology. He led the development team responsible for the U.S. registration, launch and life cycle management of Erbitux in colorectal cancer and head and neck tumors. He also was responsible for the BMS oncology clinical research team in Europe and the clinical pharmacology team supporting the oncology, immunology and anti-infective pipeline.

Shimota has nearly 30 years of professional experience in operational finance roles of increasing responsibility. Most recently, he was chief financial officer of Shaw Power, a division of The Shaw Group.